120 related articles for article (PubMed ID: 29848731)
21. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
22. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
23. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
[TBL] [Abstract][Full Text] [Related]
24. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.
Bondgaard AL; Poulsen TT; Poulsen HS; Skov BG
Cancer Biomark; 2012; 11(2-3):123-8. PubMed ID: 23011159
[TBL] [Abstract][Full Text] [Related]
25. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of EZH2 in gliomas: a meta-analysis.
Pyo JS; Kang DW
Int J Biol Markers; 2018 Jan; 33(1):62-67. PubMed ID: 28862715
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
29. PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
Shi MX; Ding X; Tang L; Cao WJ; Su B; Zhang J
BMC Cancer; 2024 Apr; 24(1):504. PubMed ID: 38644473
[TBL] [Abstract][Full Text] [Related]
30. MiR-101-3p Regulates the Viability of Lung Squamous Carcinoma Cells via Targeting EZH2.
Hou Y; Li L; Ju Y; Lu Y; Chang L; Xiang X
J Cell Biochem; 2017 Oct; 118(10):3142-3149. PubMed ID: 27966775
[TBL] [Abstract][Full Text] [Related]
31. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
33. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
34. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
35. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.
Hubaux R; Thu KL; Coe BP; MacAulay C; Lam S; Lam WL
J Thorac Oncol; 2013 Aug; 8(8):1102-6. PubMed ID: 23857401
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
38. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
Lv YF; Yan GN; Meng G; Zhang X; Guo QN
Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
[TBL] [Abstract][Full Text] [Related]
40. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
